The most common cell cultures used in antibody production today are mammalian cells as they produce glycoproteins with established therapeutic efficiency. The cloning of antibody-encoded genes into different expression hosts solved the problem of frequently lost antibody encoding genes during long-term cultivation and allowed for large-scale therapeutic production optimization. Over the years, the production of monoclonal antibodies has shifted from a reliance on hybridoma cell lines to recombinant technologies. Antibody production – eligible cell cultures Moreover, compared to other mammalian cells used in bioprocessing, CHO cells are able to produce a very high level of recombinant protein. In comparison, CHO cells have shown to be very stable in antibody expression with almost no contamination risks. This includes human cell lines which run at a greater risk for viral contamination and subsequent transmission in monoclonal antibody mAb production. To use CHO cells to express recombinant proteins in bioprocessing was a huge step forward compared to achievements with any other animal cell. Due to their large success, manufacturers use CHO cells in the different steps of recombinant antibody production: Transfection, recombinant protein production, purification and antibody expression. The use of CHO cells for the production of recombinant antibodies has led to a boost in the production process of recombinant protein therapeutics. Through CHO cell antibody production, it became possible to derive therapeutic antibodies as treatments for diseases like cancer, multiple sclerosis, asthma, HIV or neuroblastoma. CHO Cell Antibody Production with evitria CHO cell antibody production
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |